Today Alkermes Plc – Ordinary Shares (NASDAQ:ALKS) Reported Decrease in Shorted Shares

October 2, 2018 - By Peter Kolinski

Investors sentiment decreased to 0.82 in 2018 Q2. Its down 0.33, from 1.15 in 2018Q1. It dropped, as 29 investors sold Alkermes plc shares while 76 reduced holdings. 25 funds opened positions while 61 raised stakes. 152.15 million shares or 0.39% less from 152.74 million shares in 2018Q1 were reported.
Blackrock invested in 0.02% or 9.96M shares. Livforsakringsbolaget Skandia Omsesidigt invested 0.01% of its portfolio in Alkermes plc (NASDAQ:ALKS). Frontier Capital Limited holds 0.2% or 683,723 shares. Goldman Sachs Incorporated has 3.72 million shares. 21,113 were reported by Daiwa Sb Investments. C Worldwide Group Inc Hldgs A S reported 0.09% stake. Orbimed Advsrs Lc holds 0.07% or 145,000 shares in its portfolio. 10,540 were accumulated by Evercore Wealth Mngmt Limited Liability. Bancorp Of Mellon Corp holds 1.19 million shares. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Alkermes plc (NASDAQ:ALKS). 9,275 are owned by Sumitomo Mitsui Asset. S&Co holds 0.04% or 8,200 shares. The Belgium-based Kbc Nv has invested 0.05% in Alkermes plc (NASDAQ:ALKS). Credit Suisse Ag holds 0.01% or 203,598 shares in its portfolio. Mackenzie Finance accumulated 7,349 shares.

The stock of Alkermes Plc – Ordinary Shares (NASDAQ:ALKS) registered a decrease of 0.62% in short interest. ALKS’s total short interest was 7.14 million shares in October as published by FINRA. Its down 0.62% from 7.19 million shares, reported previously. With 409,500 shares average volume, it will take short sellers 17 days to cover their ALKS’s short positions. The short interest to Alkermes Plc – Ordinary Shares’s float is 4.65%.

The stock increased 1.11% or $0.47 during the last trading session, reaching $42.91. About 456,778 shares traded. Alkermes plc (NASDAQ:ALKS) has declined 25.30% since October 2, 2017 and is downtrending. It has underperformed by 40.92% the S&P500.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $6.66 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

Alkermes plc (NASDAQ:ALKS) Ratings Coverage

Among 8 analysts covering Alkermes (NASDAQ:ALKS), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. Alkermes had 9 analyst reports since April 16, 2018 according to SRatingsIntel. On Thursday, June 21 the stock rating was downgraded by Morgan Stanley to “Underweight”. As per Wednesday, May 16, the company rating was upgraded by Citigroup. Bank of America maintained it with “Buy” rating and $54 target in Friday, July 27 report. The rating was maintained by Cantor Fitzgerald with “Hold” on Thursday, May 10. The rating was maintained by Credit Suisse with “Outperform” on Friday, July 27.

More important recent Alkermes plc (NASDAQ:ALKS) news were published by: which released: “Consolidated Research: 2018 Summary Expectations for Pan American Silver, Invesco, Diodes, INVESCO …” on September 27, 2018, also published article titled: “Biotechs and biopharmas in the red”, published: “Alkermes adds Merck’s Keytruda to early-stage study of ALKS 4230 in solid tumors” on September 10, 2018. More interesting news about Alkermes plc (NASDAQ:ALKS) was released by: and their article: “The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares” with publication date: September 18, 2018.

Alkermes plc (NASDAQ:ALKS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News